Results 121 to 130 of about 636,170 (221)

New Means and Challenges in the Targeting of BTK

Bruton's tyrosine kinase (BTK) is central to the survival of malignant and normal B lymphocytes and has been a crucial therapeutic target of several generations of kinase inhibitors and newly developed degraders.
Sondhi, Anya K., Abdel-Wahab, Omar, Nawaratne, Vindhya, Taylor, Justin   +3 more
core   +1 more source

Cardiovascular Toxicity of BTK Inhibitors: A Patient-Centered Framework for Risk Stratification and Management. [PDF]

J Clin Med
Tedeschi A, Barocelli F, Gerra L, Breviario F, Sbarra F, Pagnoni G, Marasacchia G, Marangi F, Darroudi S, Di Spigno F, Coppi F, Arcari A, Losi G, Vallisa D, Niccoli G, Aschieri D, Navazio A, Tarantini L.   +17 more
europepmc   +1 more source

Optimization of furanopyrimidine-based kinase inhibitors: Identification of a BTK kinase inhibitor for the treatment of B cell lymphoma

, 2018
[[abstract]]According to the statistics from Ministry of Health and Welfare in Taiwan, non-Hodgkin's lymphoma is ranked as number nine on leading cause of cancer death toward both male and female people.
Wang, WC;Hsu, YC;Shiao, HY;Hung, HC;Kuo, CC;Lee, JC;Hsu, TA;Hsieh, HP
core  

Targeting Bruton’s Tyrosine Kinase (BTK) in Autoimmunity: Achievements, Opportunities and Challenges

Drug Design, Development and Therapy
Sebastian Torke,1,* Sarah Dybowski,2,* Martin S Weber2– 41Experimental and Clinical Research Center, Charité-Medical Center Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany; 2Department of Neurology, University ...
Torke S, Dybowski S, Weber MS
doaj  

Mechanisms of resistance to BTK inhibitors in B cell malignancies and emerging targeted strategies. [PDF]

Mol Ther Oncol
Ni Q, Rui L.
europepmc   +1 more source

Generational safety profiles of BTK inhibitors: adverse reaction signals and real-world evidence from the FAERS database. [PDF]

Front Med (Lausanne)
Tu J, Wang Z, Zhang J, Xu H, Li Y, Zhang L, Gong J, Zhao L.   +7 more
europepmc   +1 more source

Comparative Efficacy of BTK Inhibitors in Treatment-Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis. [PDF]

J Cell Mol Med
Xu F, Zou X, Yang Y, Zhou K, Huang W.
europepmc   +1 more source

Managing Waldenström's macroglobulinemia with BTK inhibitors. [PDF]

Leukemia, 2023
Buske C, Jurczak W, Salem JE, Dimopoulos MA.   +3 more
europepmc   +1 more source

Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia. [PDF]

Future Oncol
Hou JZ, Choksi R, Maglinte GA, Wang X, Rui PA, Suryavanshi M, Allendorf D, Patel T, Dadla A, Fontaine A, Jonglertham P, Aton L, Hagan M, Morere L, Scott J, Williams R, Ermann DA.   +16 more
europepmc   +1 more source

The Immunologic Paradox of BTK Inhibitors in Chronic Lymphocytic Leukemia: Selectivity, Hypogammaglobulinemia, and Infection Risk. [PDF]

Cancers (Basel)
Andreescu M, Tudorache SI, Moldovan CA, Moldovan AD, Cochior D, Popov V, Andreescu B, Ionescu D, Padurariu-Covit MD.   +8 more
europepmc   +1 more source